Table 4.
Changes in Imunophenotype (Mean, SD) for MSBR (n=12) and Control (n=8) Group, Obtained by One-Sample Wilcoxon Test
| Baseline (Mean ± SD) | Visit 2 (Mean ± SD) | Wilcoxon Test Value | p-value | Baseline (Mean ± SD) | Visit 2 (Mean ± SD) | Wilcoxon Test Value | p-value | |
|---|---|---|---|---|---|---|---|---|
| % phagocyting cells | 15.10 ± 6.82 | 14.58 ± 9.52 | 31.00 | 0.57 | 19.61 ± 7.13 | 16.51 ± 9.60 | 4.00 | 0.22 |
| Monocyte subsets | ||||||||
| Classical (%) | 84.58 ± 4.33 | 80.14 ±5.72 | 8.00 | 0.05 | 82.21 ± 6.39 | 81.90 ± 6.49 | 7.00 | 1.00 |
| Intermediate (%) | 4.29 ± 2.05 | 5.43 ± 2.41 | 57.00 | 0.53 | 4.92 ± 2.50 | 4.45 ± 1.90 | 10.00 | 1.00 |
| Non-classical (%) | 5.05 ± 2.78 | 7.06 ± 3.74 | 67.50 | 0.08 | 6.50 ± 3.50 | 6.60 ± 2.37 | 13.00 | 1.00 |
| Changes in activation of monocyte subsets | ||||||||
| MHC-II on classical (GMF) | 442.00 ± 94.58 | 465.33 ± 90.98 | 50.50 | 0.39 | 466.83 ± 122.54 | 413.33 ± 99.63 | 4.00 | 0.22 |
| MHC-II on intermediate (GMF) | 1203.67 ± 298.74 | 1262.08 ± 306.91 | 43.00 | 0.79 | 1349.0 ± 368.96 | 1363.83 ± 318.88 | 12.00 | 0.84 |
| MHC-II on non-classical (GMF) | 608.33 ± 202.94 | 580.25 ± 168.65 | 27.00 | 0.38 | 692.33 ± 236.97 | 629.67 ± 190.19 | 5.00 | 0.31 |
| CD86 on classical (GMF) | 363.17 ± 39.15 | 290.83 ± 68.84 | 5.00 | 0.01 | 359.50 ± 51.27 | 318.33 ± 41.83 | 0.00 | 0.03 |
| CD86 on intermediate (GMF) | 562.08 ± 118.49 | 507.75 ± 124.79 | 12.00 | 0.03 | 535.50 ± 81.35 | 494.50 ± 79.41 | 1.00 | 0.06 |
| CD86 on non-classical (GMF) | 393.50 ± 117.62 | 357.17 ± 84.07 | 23.50 | 0.24 | 384.0 ± 100.02 | 371.17 ± 48.76 | 6.00 | 0.40 |
| Plasma analysis | ||||||||
| hsCRP (mg/l) | 1.57 ± 1.65 | 1.49 ± 1.55 | −11.00 | 0.63 | 1.72 ± 1.66 | 1.15 ± 1.62 | −7.00 | 0.56 |
| IL-6 (pg/mL) | 1.57 ± 0.65 | 2.00 ± 1.31 | 24.00 | 0.32 | 2.40 ± 1.82 | 2.48 ± 2.86 | 2.00 | 0.95 |
| TNF-α (pg/mL) | 1.12 ± 0.32 | 1.29 ± 0.44 | 38.00 | 0.10 | 1.07 ± 0.38 | 1.02 ± 0.37 | −20.00 | 0.20 |
Note: Bold formatting indicates significant results.